To describe autoantibodies (Abs) against tripartite motif-containing (TRIM) protein 9 and 67 in two patients with paraneoplastic cerebellar degeneration (PCD) associated with lung adenocarcinoma. Abs were characterized using immunohistochemistry, Western blotting, cultures of murine cortical, and hippocampal neurons, immunoprecipitation, mass spectrometry, knockout mice for Trim9 and 67, and cell-based assay. Control samples included sera from 63 patients with small cell lung cancer without any paraneoplastic neurological syndrome, 36 patients with lung adenocarcinoma and PNS, CSF from 100 patients with autoimmune encephalitis, and CSF from 165 patients with neurodegenerative diseases. We found Abs targeting TRIM9 and TRIM67 at high concentration in the serum and the cerebrospinal fluid (CSF) of a 78-year-old woman and a 65-year-old man. Both developed subacute severe cerebellar ataxia. Brain magnetic resonance imaging found no abnormality and no cerebellar atrophy. Both had CSF inflammation with mild pleiocytosis and a few oligoclonal bands. We identified a pulmonary adenocarcinoma, confirming the paraneoplastic neurological syndrome in both patients. They received immunomodulatory and cancer treatments without improvement of cerebellar ataxia, even though both were in remission of their cancer (for more than 10 years in one patient). Anti-TRIM9 and anti-TRIM67 Abs were specific to these two patients. All control serum and CSF samples tested were negative for anti-TRIM9 and 67. Anti-TRIM9 and anti-TRIM67 Abs appeared to be specific biomarkers of PCD and should be added to the panel of antigens tested when this is suspected.
Introduction
Paraneoplastic cerebellar degeneration (PCD) is a rare neurological syndrome characterized by subacute cerebellar ataxia associated with a systemic tumor [1] . Neurological symptoms frequently precede cancer detection. The diagnosis is mainly based on the identification of specific autoantibodies (Abs) in the serum and/or CSF of patients [1, 2] . The first described, and the most frequent, are anti-Yo Abs, also named antiPurkinje cell cytoplasmic antibody-type 1 (PCA1) [3] , but more than 30 other Abs have also been described in PCD (for review, see [2] ). Although the role of these Abs in the pathophysiology of PCD is unclear, they represent a precious biomarker allowing prompt diagnosis. In clinical practice, many patients have clinical presentation of PCD without characterized associated Abs [4] . Herein, we describe novel Abs targeting the brain antigens tripartite motif-containing (TRIM) protein 9 (TRIM9) and 67 (TRIM67) in two patients with PCD and lung adenocarcinoma.
Materials and Methods

Patients
Between October 2007 and June 2016, we tested more than 8000 CSF samples of patients suspected of autoimmune encephalitis or paraneoplastic neurological syndrome in the French reference center. Among them, using immunohistochemistry, we identified 32 samples with Abs directed against uncharacterized neuronal targets and with clinical presentation highly suggestive of PCD. To perform future characterization, samples of these patients were deposited in the "NeuroBioTec" biobank of the Hospices Civils de Lyon (France, AC-208-73, NFS96-900). To evaluate the specificity of anti-TRIM9/TRIM67 Abs, we also tested sera from 63 patients with small cell lung cancer but without any paraneoplastic neurological syndrome, 36 patients with lung adenocarcinoma and PNS (7 with Ma2, 16 with Hu, and 13 without antibodies), CSF from 100 patients with autoimmune encephalitis (29 patients with an associated cancer, and 71 without), and CSF of 165 patients with no inflammatory neurodegenerative diseases (25 with fronto-temporal dementia, 15 Lewy body disease, 20 with psychosis, 15 with communicant hydrocephalus, and 90 with Alzheimer's disease).
Written consent was obtained from all patients, and the study was approved by the institutional review board of the University Claude Bernard Lyon 1 and Hospices Civils de Lyon. All clinical and paraclinical data of these patients were collected by study investigators and clinical research associates at the time of PCD diagnosis and during follow-up.
Mice
Mouse lines were on a C57BL/7 background and were housed and bred at the University of North Carolina with approval from the Institutional Animal Care and Use Committee. Timed pregnant females were obtained by placing male and female mice together overnight; the following day was designated as E0.5 if the female had a vaginal plug. Trim9 −/− mice and Trim67 −/− mice have been previously described [5, 6] .
Trim9
−/− :Trim67 −/− mice, generated by crossing Trim9 −/− mice and Trim67 −/− mice, were viable and will be described in more detail below.
Immunohistochemistry
Freshly prepared adult rat and mouse brains were fixed in 4% paraformaldehyde (PFA) for 1 h, frozen, and sliced into 10-μm-thick sections. Immunolabeling was performed using patient CSF (1:10) and revealed with peroxidase-conjugated secondary antibody against human IgGs (1:1000, 709-065-149 J, Jackson Immunoresearch, Immunotech, Montluçon, France). For fluorescent labeling, immunostaining was revealed with appropriate Alexa fluorophore-conjugated secondary antibodies (1:1500, A11013, Thermofisher, Courtaboeuf, France).
Western Blot
Whole adult rat brains were dislocated. The tissue was homogenated in lysis buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, orthovanadate, benzonase, phosphatase inhibitor, and protease inhibitor. The homogenate was incubated on ice for 30 min then sonicated. Cell debris was discarded by 10 min centrifugation at 10000g and 4°C. Twenty micrograms of whole brain protein extract was used for Western blotting to screen specific band recognized by patient CSF (1/100).
Immunoprecipitation and Mass Spectrometry-Based Identification
A positive CSF (patient 1) and a negative CSF (control CSF) were used. Five microliters of CSF was mixed with 50 μL of protein G-conjugated agarose beads (Sigma-Aldrich, Lyon, France) and completed to 500 μL with PBS. The mixture was incubated for 2 h at 4°C with rotation to allow for coupling of CSF antibodies to protein G. Simultaneously, whole protein extract from one mouse brain was prepared and incubated with 50 μL of agarose beads. Nonspecific contaminant was removed from the lysate by 5 min centrifugation at 16000g and 4°C. Cleared lysate was subsequently used for immunoprecipitation with antibody-conjugated agarose beads. Immunoprecipitate was analyzed by SDS-PAGE, and this was followed by silver-stain and Western blotting. The area between 72 and 95 kDa of a Coomassie-blue stained gel was excised and analyzed by mass spectrometry-based proteomics, as previously described [7] . Briefly, proteins were in-gel digested using modified trypsin (sequencing grade, Promega, Charbonnières, France), and resulting peptides were analyzed by online nanoLC-MS/MS (UltiMate 3000 and LTQ-Orbitrap Velos Pro, Thermo Scientific, Grenoble, France). Peptides and proteins from different samples were identified, filtered, and compared using Mascot and Proline software (Profi Proteomics, Toulouse, France).
Cell-Based Assay
To confirm the target of the Abs, HEK 293 cells were transfected with pCS2-Trim9(mouse) plasmid [8] [9] . For epitope mapping on TRIM67, we generated three constructions coding for the Nterminal region (F1), B-Box domain (F2), and C-terminal region containing Coiled-coil, FnBD, and B30.2 domains (F3), using PCR (In fusion, Clontech, Mountain View, CA) and primers as indicated in Table 1 .
Effects of Patient CSF on Neuronal Viability and Development
Embryonic day (E) 15.5 cortical neurons were dissociated from wildtype (+/+) and
mice and cultured on Poly-D-Lysine (Sigma-Aldrich) coated coverslips for 96 h in Neurobasal media supplemented with glutamine and b27 (Invitrogen, Carlsbad, CA) prior to fixation in 4% PFA in PHEM buffer. Neurons were left untreated, or incubated with patient CSF (1:100) for either 1 or 3 days prior to fixation. Neurons were stained for filamentous actin (phalloidin), βIII tubulin (neuronal marker), and nuclei (DAPI). Neurons were imaged by widefield epifluorescence with a × 20, 1.3 NA PlanApo objective on an inverted Olympus IX-81ZDC microscope with an iXon 1K EM-CCD camera (Oxford Instruments, Concord, MA). Viable and nonviable cells were counted as spread nuclei with visible nucleoli and contracted nuclei without visible nuclei, respectively; differences were tested using an ANOVA with no post hoc correction. Neurites were measured using the NeuronJ plugin in ImageJ. The longest neurite was considered the axon. Several parameters were measured per neuron, including density of axon branches, primary axon length, total axonal material (summed length of all axon and branches), dendritic material (summed length of all dendrites and branches), primary dendrite number, and dendrite branch points. ANOVA with Bonferroni post hoc correction was performed to compare treatments to untreated control and to compare the two genotypes in the untreated condition. Corrected p values are shown for significant differences. For all tests, p < 0.05 was considered significant.
Results
TRIM9 and TRIM67 Are Targeted by CSF Autoantibodies of Two Patients with PCD
Among the 32 samples of patients with suspected PCD and Abs directed against uncharacterized neuronal targets, the CSF of patient 1 was identified as having particular reactivity with the cytoplasm of neurons and neuropil of the cerebellum, hippocampus, and cerebral cortex that was distinct from known Abs associated with PCD (Fig. 1a, upper panels) . Indirect immunohistochemistry on rat brain section found diffuse immunoreactivity in the cytoplasm of the soma and proximal dendrite of CA3 neurons in the hippocampus (Fig. 1b, upper panels) . In the cerebellum, marked immunolabeling was observed in neuropil of the molecular layer, in cell bodies and dendrites of Purkinje cells, and to a less extent in the cytoplasm of granule cells (Fig. 1b , lower panels). Immunostaining of fixed and permeabilized murine neurons found labeling of cytosolic clusters (Fig. 1c) . However, no labeling was observed on live neurons, suggesting that the Abs exclusively targeted intracellular proteins. Western-blots using rodent brain protein extract showed that CSF from patient 1 recognized two specific protein bands at~72 and~95 kDa (Fig. 1d) . To identify the antigen, whole mouse brain homogenate was incubated with CSF from patient 1, and the antigen was immunoprecipitated. Subsequent mass spectrometry analyses found that TRIM9 and TRIM67 were specifically enriched in the 95-kDa band and that the 72-kDa band also contained TRIM9, but not TRIM67.
To confirm the presence of anti-TRIM9 and TRIM67-Abs in CSF from patient 1, HEK293 cells were transfected with full-length cMyc-tagged TRIM9 or TRIM67 plasmids. The CSF recognized both TRIM9-and TRIM67-expressing cells, demonstrating that the CSF contained Abs recognizing the two proteins; control CSF did not (Fig. 2a) . No staining was observed on double KO mice brain slices (Fig. 2b) , indicating that the Abs in the CSF from patient 1 were only raised against TRIM9 and TRIM67. Immunostaining on Trim9 −/− single KO mouse brain found expression of TRIM67, and on Trim67 −/− mouse brain found expression of TRIM9 (Fig. 2b) ; TRIM9 was widely expressed, notably in the hippocampus, and TRIM67 in the cerebellum, as previously described [6] .
The 31 other patients with suspected PCD were screened using the HEK293 transfected cells and a second patient with anti-TRIM9 and anti-TRIM67-Abs in her CSF (patient 2; Supplemental fig. S1 ). 3 ; more than 10 oligoclonal bands ( O C B s ) ; I g G i n d e x o f 1 . 5 2 ( n o r m a l < 0 . 7 ) ) . A fluorodeoxyglucose body positron-emission tomography (PET) scan found a mediastinal highly metabolic lymph node, and a biopsy found the presence of a poorly differentiated adenocarcinoma (CK7 and TTF1 positive, without EGFR, KRAS, BRAF, or ERBB2 mutation). The patient was treated by chemotherapy (carboplatine and taxol), corticosteroids, and immunoglobulins without effect on the neurological symptoms and with a partial effect on the cancer. She is still alive 2 years after disease onset.
Patient 2
A 65-year-old man, with past medical history characterized by 80 pack-years of cigarettes and pulmonary right lobar well-differentiated adenocarcinoma (stage 1B T2N0), was diagnosed 2 years before and treated by surgery only. He developed subacutely (within less than 1 month) isolated and severe cerebellar ataxia. The patient was unable to walk without support and developed dysarthria. Examination found a severe static cerebellar syndrome with extension of the support polygon and inability to stand up without help. A mild dysmetria and hypermetria were also observed, predominantly on the left side. No motor, sensory, or cognitive deficit was observed. Initial brain computed tomography scan was normal and the CSF showed inflammation (protein 0.41 g/l; lymphocytes 9/mm 3 with activated lymphoplasmocytes; few OCBs; an IgG index of 0.65 (normal < 0.7)). A fluorodeoxyglucose body PET scan showed a mediastinal highly metabolic lymph node 1.5 cm in size suggesting a metastatic evolution of the pulmonary adenocarcinoma. The patient refused further investigations, all immunomodulatory treatment and was lost of follow-up during 10 years after mediastinal radiotherapy. Twelve years later, the patient is still alive with a stable but severe cerebellar ataxia and without recurrence of his cancer.
Specificities of Patients 1 and 2 Abs
The technique of "end-point dilution" on HEK293 cells was employed to estimate Ab titers in the serum and the CSF of the two positive patients. Patient 1 had higher anti-TRIM9 Ab titer than patient 2 (serum 1/128,000, CSF 1/8000 versus 1/64000 and 1/4000, respectively), while anti-TRIM67 Ab titers in both patients were identical (serum 1/256000, CSF 1/8000).
As Abs against TRIM46, a closely related class I (I-3) member of the TRIM family, have been described in three TRIM9 was expressed widely in the adult brain while TRIM67 is more restricted to the cerebellum patients having paraneoplastic neurological syndromes [10] , we tested whether the Abs also recognized TRIM46; both patients were negative (Supplemental fig. S1 ).
To ensure that anti-TRIM9 and TRIM67-Abs were specific to PCD, we tested transfected HEK cells expressing TRIM9 or TRIM67 with sera and CSF of 364 controls; all were negative.
Characteristics of TRIM-Abs
Analysis of IgG composition found that CSF of both patients contained mainly IgG1 and that other IgG subclasses (IgG2, 3, and 4) were only very weakly positive (Fig. 3a) . DNA constructs coding for different domains of TRIM9 and TRIM67 were used to probe the protein domain containing the epitope for the Abs. Results from Western blotting experiments indicated that Abs in the CSF of both patients were polyclonal, since Abs recognized at least two different epitopes on the TRIM9 protein, one in the RING domain and the other in B-Box, Coiled-coil or FnBD-3 domain, but not the B30.2 (Fig. 3b) . On the TRIM67, Abs reacted strongly with the B-Box domain (double KO) mice were treated with patient CSF (1:100) for 3 days or 1 day prior to fixation. Neurons were stained for ßIII tubulin (green), filamentous actin (red), and DNA (blue). Several parameters were measured per neuron, including density of axon branches, primary axon length, total axonal material, dendritic material, primary dendrite number, and dendrite branch points. In the box and whisker plots: the cyan boxes for each genotype are untreated. The second two were incubated from the 24th to the 96th hour (3 days) with 1:100 CSF from patient 1 (magenta boxes) and patient 2 (yellow boxes), respectively; the next two were incubated from the 72nd to the 96th hour (1 day), patient 1 and patient 2, respectively. Boxplots depict median ± the interquartile range (IQR), and whiskers reach minimum and maximum values. p values were determined by ANOVA, comparisons made to untreated control, with Bonferroni post hoc corrections of the number of comparisons made. p values are considered significant when p < 0.05. No consistent significant effects of patients' CSF on neurons were observed and the one in C-terminal containing Coiled-coil, FnBD-3, and B30.2 domain. Unlike TRIM9, the TRIM67 N-terminal containing RING domain was very weakly recognized by the Abs (Supplemental fig. S2 ).
Effect of CSF Autoantibodies on Neurons
TRIM9 and TRIM67 have both been implicated in the morphogenesis of developing neurons or neuron-like cells [5, 8, 11] . To investigate a potential pathogenic mechanism and examine whether Abs affect TRIM-dependent neuronal morphogenesis, the effect of patient CSF on developing murine cortical neurons was studied in vitro. No significant effect of antibodies on neuron viability or consistent detriment to neuronal morphogenesis was observed (Fig. 4) .
Discussion
The results of the present study demonstrate that TRIM9 and TRIM67 are new targets of Abs in PCD associated with lung carcinoma. These Abs appear to be highly specific biomarkers, since they were not found in the CSF or sera of control patients. These results are reinforced by the previous identification of anti-TRIM9 and anti-TRIM67-Abs in a woman with PCD secondary to a melanoma [12] , suggesting that other cancers could also be the trigger of such antibodies. Exploratory epitope mapping found that the immune reaction was polyclonal, with Abs that recognize multiple epitopes on the two proteins. These Abs are mainly of IgG1 subtype. The TRIM protein family is a highly conserved superfamily of E3 ubiquitin ligases that include 76 members; TRIM9 and TRIM67 belong to the class I-2 [13] . Antibodies targeting TRIM21 and 46 have been described in other autoimmune diseases. For instance, the presence of anti-TRIM21 Abs (Ro52) in serum has been described in association with different immune-mediated diseases such as Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis, and autoimmune myositis (for review, see [14] ). More recently, anti-TRIM46 Abs have been described in three patients with paraneoplastic neurological syndromes associated with small cell lung carcinoma [10] . Although both patients presented herein were negative for anti-TRIM46, the serum of patient 1 was found to be positive for anti-TRIM21 Abs using standard diagnostic tests (dot-blot and luminex, data not shown); the serum of patient 2 was negative. However, as no immunostaining with patient CSF was observed on the brain of Trim9 −/− and Trim67 −/− double KO mice, we can conclude that CSF of the two patients described herein contained only anti-TRIM9 and anti-TRIM67 Abs; positivity for anti-TRIM21-Abs positivity in the serum of patient 1 could be a consequence of a cross-reactivity. TRIM9 is widely expressed in embryonic and adult mouse brain [15, 16] . In the latter, TRIM9 localizes in the cytoplasm and proximal dendrites of pyramidal cells in the hippocampus, the Purkinje cells of the cerebellum, and in the external layer of the cortex [9, 16] . Immunostaining of Trim67 −/− mouse brain confirmed these observations. TRIM67 is abundantly expressed in the cerebellum of both mouse and human [6, 11] , and immunostaining with patient CSF herein showed a similar pattern. The two patients reported herein developed subacute severe cerebellar ataxia. Lung carcinoma was discovered and treated; however, neurological symptoms persisted which could be due to irreversible neuronal loss. In addition, patient 1, having a higher anti-TRIM9 Ab titer, developed more severe neurological impairment including cognitive impairment with anterograde amnesia and dysexecutive symptoms, which were absent in patient 2.
Although it lacks any identified membrane targeting domain, TRIM9 does interact with the membrane-associated SNARE protein, SNAP25, and acts as negative regulator of exocytosis during axonal branching and growth [5] . TRIM9 also interacts with and ubiquitinates DCC, a transmembrane receptor for netrin-1 [5, 17] , and the actin polymerase VASP [8] . Upon binding of netrin-1 to its receptor DCC, TRIM9 releases SNAP25 and VASP is deubiquitinated, promoting vesicle fusion, membrane expansion, and membrane protrusion [5, 8] . In patients with dementia and Lewy bodies, TRIM9 expression in the brain is reduced [9] . Furthermore, in animal models, absence of TRIM9 causes excessive dendrite arborization, mislocalization, and decreased dendritic density in adult-born neurons of the dentate gyrus, leading to impairment of learning and memory [18] . TRIM67 interacts with TRIM9 and DCC and plays an important role in brain development and behavior, including learning and memory and cognitive flexibility [6] . These two proteins seem therefore to play a major role in neuronal function, and we therefore investigated the pathogenicity of Abs on neurons. However, we did not observe any effect of patient CSF on cortical neuron survival or growth in vitro. As immunostaining on living neurons was negative, the absence of direct interaction between Abs and the antigen is probable explaining the absence of pathogenic effect. This result is similar to other onconeural Abs targeting intracellular antigens [19, 20] .
To conclude, the present study demonstrates that Abs against TRIM9 and TRIM67 are biomarkers of some rare cases of PCD and seem to be mainly associated with lung carcinoma. Anti-TRIM9 and TRIM67 Abs should be added to the routine diagnostic tests performed for patients with suspicion of PCD and negative for previously described Abs. Furthermore, efforts must be made to provide prompt diagnosis and to try early immunomodulatory treatment as cerebellar ataxia seems to be irreversible owing to neuronal death. 
